Santaris announces Strategic Alliance with Bristol-Myers Squibb - Gilde Healthcare

Santaris announces Strategic Alliance with Bristol-Myers Squibb

April 17, 2013

Hørsholm, Denmark / San Diego, California — Santaris Pharma A/S, a privately held biopharmaceutical company announced a worldwide strategic alliance with Bristol-Myers Squibb (NYSE: BMY) to develop novel medicines using Santaris Pharma’s proprietary Locked Nucleic Acid (LNA) Drug Platform.

Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $10 million, up to $90 million in potential milestone payments per product and funding of ongoing discovery and research activities. In addition, Santaris Pharma will be eligible to receive royalties on the worldwide sales of all medicines arising from the alliance.

About Santaris Pharma A/S

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.

Please visit www.santaris.com for more information.

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022

Gilde Healthcare Company Volta Medical publishes clinical results on AI based solution for patients in atrial fibrillation

Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s...
September 2, 2022